MX2021004656A - Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa. - Google Patents

Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa.

Info

Publication number
MX2021004656A
MX2021004656A MX2021004656A MX2021004656A MX2021004656A MX 2021004656 A MX2021004656 A MX 2021004656A MX 2021004656 A MX2021004656 A MX 2021004656A MX 2021004656 A MX2021004656 A MX 2021004656A MX 2021004656 A MX2021004656 A MX 2021004656A
Authority
MX
Mexico
Prior art keywords
plasma concentrations
patient variability
levodopa plasma
levodopa
inter
Prior art date
Application number
MX2021004656A
Other languages
English (en)
Inventor
Martin Freed
Richard Batycky
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2021004656A publication Critical patent/MX2021004656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para reducir la variabilidad entre pacientes de las concentraciones plasmáticas de levodopa en una población de pacientes con enfermedad de Parkinson. Los métodos de la invención comprenden administración pulmonar de levodopa en concentraciones terapéuticamente efectivas de tal manera que la variabilidad entre pacientes de las concentraciones plasmáticas de levodopa en períodos que van desde aproximadamente 10 minutos después de la inhalación a aproximadamente 60 minutos o más después de la inhalación tienen menos del 50% de coeficiente de variación. Los métodos de la invención son específicamente útiles para el tratamiento de fluctuaciones motoras que surgen como un efecto secundario de la terapia de L-Dopa.
MX2021004656A 2012-10-22 2013-10-21 Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa. MX2021004656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716753P 2012-10-22 2012-10-22
PCT/US2013/065834 WO2014066206A1 (en) 2012-10-22 2013-10-21 Reducing inter-patient variability of levodopa plasma concentrations

Publications (1)

Publication Number Publication Date
MX2021004656A true MX2021004656A (es) 2022-08-22

Family

ID=50545140

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005039A MX2015005039A (es) 2012-10-22 2013-10-21 Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa.
MX2021004656A MX2021004656A (es) 2012-10-22 2013-10-21 Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015005039A MX2015005039A (es) 2012-10-22 2013-10-21 Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa.

Country Status (15)

Country Link
US (1) US9295661B2 (es)
EP (1) EP2908804A4 (es)
JP (2) JP2015534988A (es)
KR (1) KR102237007B1 (es)
CN (2) CN105050581B (es)
AU (3) AU2013334947B2 (es)
BR (1) BR112015009086A2 (es)
CA (1) CA2888979A1 (es)
HK (3) HK1212257A1 (es)
MX (2) MX2015005039A (es)
NZ (2) NZ747373A (es)
RU (1) RU2682681C2 (es)
SG (1) SG11201503128TA (es)
WO (1) WO2014066206A1 (es)
ZA (1) ZA201503631B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DK1531798T3 (da) * 2002-03-20 2012-08-13 Civitas Therapeutics Inc Pulmonal frigørelse af Levodopa
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
KR101569604B1 (ko) * 2007-12-28 2015-11-16 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
CA2888994C (en) * 2012-10-22 2022-10-04 Civitas Therapeutics, Inc. Levodopa formulations for rapid relief of parkinson's disease

Also Published As

Publication number Publication date
EP2908804A4 (en) 2016-07-13
CN107982246A (zh) 2018-05-04
CN105050581A (zh) 2015-11-11
SG11201503128TA (en) 2015-05-28
HK1217094A1 (zh) 2016-12-23
NZ747373A (en) 2020-02-28
ZA201503631B (en) 2017-11-29
KR20150101993A (ko) 2015-09-04
CN105050581B (zh) 2018-01-19
CA2888979A1 (en) 2014-05-01
MX2015005039A (es) 2015-12-01
BR112015009086A2 (pt) 2017-07-04
JP2015534988A (ja) 2015-12-07
RU2015119376A (ru) 2016-12-10
KR102237007B1 (ko) 2021-04-06
AU2020250280A1 (en) 2020-11-05
US20160015663A1 (en) 2016-01-21
US9295661B2 (en) 2016-03-29
AU2013334947B2 (en) 2018-08-09
HK1212257A1 (en) 2016-06-10
RU2682681C2 (ru) 2019-03-20
JP2019038857A (ja) 2019-03-14
AU2020250280B2 (en) 2022-06-02
AU2018253542A1 (en) 2018-11-22
AU2018253542B2 (en) 2020-07-02
AU2013334947A1 (en) 2015-06-11
HK1254400A1 (zh) 2019-07-19
WO2014066206A1 (en) 2014-05-01
NZ708415A (en) 2018-11-30
EP2908804A1 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2021000715A (es) Composiciones y metodos para tratar trastornos metabolicos.
IN2015DN03219A (es)
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
AU2018253542A1 (en) Reducing inter-patient variability of levodopa plasma concentrations
IN2014MN02382A (es)
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.
IN2013MU01248A (es)
IN2013MU01244A (es)
IN2013MU01245A (es)
IN2013MU01247A (es)
IN2013MU01249A (es)
IN2013MU01250A (es)
IN2013MU01246A (es)
BR112015002384A2 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
IN2013MU01243A (es)